218 related articles for article (PubMed ID: 8475126)
1. Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice.
Gishizky ML; Johnson-White J; Witte ON
Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3755-9. PubMed ID: 8475126
[TBL] [Abstract][Full Text] [Related]
2. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
Pear WS; Miller JP; Xu L; Pui JC; Soffer B; Quackenbush RC; Pendergast AM; Bronson R; Aster JC; Scott ML; Baltimore D
Blood; 1998 Nov; 92(10):3780-92. PubMed ID: 9808572
[TBL] [Abstract][Full Text] [Related]
3. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
Zhang X; Ren R
Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
[TBL] [Abstract][Full Text] [Related]
4. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
[TBL] [Abstract][Full Text] [Related]
5. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
Gross AW; Ren R
Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
[TBL] [Abstract][Full Text] [Related]
6. Disease progression in a murine model of bcr/abl leukemogenesis.
van Etten RA
Leuk Lymphoma; 1993; 11 Suppl 1():239-42. PubMed ID: 8251903
[TBL] [Abstract][Full Text] [Related]
7. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
[TBL] [Abstract][Full Text] [Related]
8. Blast crisis in a murine model of chronic myelogenous leukemia.
Daley GQ; Van Etten RA; Baltimore D
Proc Natl Acad Sci U S A; 1991 Dec; 88(24):11335-8. PubMed ID: 1763047
[TBL] [Abstract][Full Text] [Related]
9. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.
Koschmieder S; Göttgens B; Zhang P; Iwasaki-Arai J; Akashi K; Kutok JL; Dayaram T; Geary K; Green AR; Tenen DG; Huettner CS
Blood; 2005 Jan; 105(1):324-34. PubMed ID: 15331442
[TBL] [Abstract][Full Text] [Related]
10. v-abl causes hematopoietic disease distinct from that caused by bcr-abl.
Scott ML; Van Etten RA; Daley GQ; Baltimore D
Proc Natl Acad Sci U S A; 1991 Aug; 88(15):6506-10. PubMed ID: 1862078
[TBL] [Abstract][Full Text] [Related]
11. Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder.
Hao SX; Ren R
Mol Cell Biol; 2000 Feb; 20(4):1149-61. PubMed ID: 10648600
[TBL] [Abstract][Full Text] [Related]
12. BCR/ABL induces multiple abnormalities of cytoskeletal function.
Salgia R; Li JL; Ewaniuk DS; Pear W; Pisick E; Burky SA; Ernst T; Sattler M; Chen LB; Griffin JD
J Clin Invest; 1997 Jul; 100(1):46-57. PubMed ID: 9202056
[TBL] [Abstract][Full Text] [Related]
13. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.
Kelliher MA; McLaughlin J; Witte ON; Rosenberg N
Proc Natl Acad Sci U S A; 1990 Sep; 87(17):6649-53. PubMed ID: 2204061
[TBL] [Abstract][Full Text] [Related]
14. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
Roumiantsev S; de Aos IE; Varticovski L; Ilaria RL; Van Etten RA
Blood; 2001 Jan; 97(1):4-13. PubMed ID: 11133737
[TBL] [Abstract][Full Text] [Related]
15. The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice.
Million RP; Aster J; Gilliland DG; Van Etten RA
Blood; 2002 Jun; 99(12):4568-77. PubMed ID: 12036890
[TBL] [Abstract][Full Text] [Related]
16. Hematologic disease induced in BALB/c mice by a bcr-abl retrovirus is influenced by the infection conditions.
Elefanty AG; Cory S
Mol Cell Biol; 1992 Apr; 12(4):1755-63. PubMed ID: 1312670
[TBL] [Abstract][Full Text] [Related]
17. Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models.
Doki N; Kitaura J; Uchida T; Inoue D; Kagiyama Y; Togami K; Isobe M; Ito S; Maehara A; Izawa K; Kato N; Oki T; Harada Y; Nakahara F; Harada H; Kitamura T
Int J Hematol; 2012 Feb; 95(2):167-75. PubMed ID: 22189847
[TBL] [Abstract][Full Text] [Related]
18. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
[TBL] [Abstract][Full Text] [Related]
19. Absence of bcr/abl gene in single hemopoietic progenitors in some patients with chronic myelogenous leukemia.
Misawa M; Maeda H; Hara H; Yamamoto Y; Furuyama J
Stem Cells; 1993 Nov; 11(6):536-42. PubMed ID: 7509222
[TBL] [Abstract][Full Text] [Related]
20. Proliferating status of peripheral blood progenitor cells from patients with BCR/ABL-positive chronic myelogenous leukemia.
Krämer A; Löffler H; Bergmann J; Hochhaus A; Hehlmann R
Leukemia; 2001 Jan; 15(1):62-8. PubMed ID: 11243401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
